4D Molecular Therapeutics (FDMT) Current Deferred Revenue (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Current Deferred Revenue data on file, last reported at $360000.0 in Q1 2026.

• On a quarterly basis, Current Deferred Revenue fell 58.43% year-over-year to $360000.0 in Q1 2026; TTM through Mar 2026 was $360000.0, a 58.43% decrease from a year earlier, with the FY2025 full-year figure at $360000.0, up 40.08% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $360000.0, roughly flat from $360000.0 in the prior quarter.
• Over the last five years, Current Deferred Revenue for FDMT reached as high as $3.9 million in Q1 2022 and fell as low as $257000.0 in Q4 2024.
• Historically, Current Deferred Revenue has averaged $1.2 million across 5 years, with a median of $1.2 million in 2023.
• Across the five-year window, Current Deferred Revenue plunged 86.07% in 2023 and surged 69.92% in 2024, its largest moves.
• Year by year, Current Deferred Revenue stood at $2.0 million in 2022, then plunged by 86.07% to $273000.0 in 2023, then retreated by 5.86% to $257000.0 in 2024, then jumped by 40.08% to $360000.0 in 2025, then changed by 0.0% to $360000.0 in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $360000.0 in Q1 2026, $360000.0 in Q4 2025, and $360000.0 in Q3 2025.